Atg4B activator-1 (Compound 16a) is an allosteric, selective, and orally active ATG4B activator with a Kd of 0.2199 μM. Atg4B activator-1 binds to the allosteric pocket of ATG4B and induces conformational changes. Atg4B activator-1 induces Autophagy. Atg4B activator-1 inhibits the proliferation and migration of triple-negative breast cancer cells. Atg4B activator-1 can be used in studies related to triple-negative breast cancer.

AR-102 free acid, an active metabolite of AR-102, is a prostaglandin F (PGF) derivative.

Antimicrobial agent-46 is a inhibitor of Salmonella typhimurium serine acetyltransferase (StSAT) with an IC50 of 48.6 μM. Antimicrobial agent-46 inhibits bacterial growth in minimal medium lacking cysteine (LB 20%). Antimicrobial agent-46 exerts its effect by targeting the cysteine biosynthesis pathway, which is crucial for bacterial persistence and adaptability. Antimicrobial agent-46 exhibits antibacterial activity against the Gram-negative bacterium Escherichia coli. Antimicrobial agent-46 can be used in infection-related research .

AM-112 is a β-lactamase (β-lactamase) inhibitor and antibacterial agent, with IC50 values ranging from 0.0002 μg/mL to 0.67 μg/mL against class A, C, and D β-lactamase. By inhibiting PBP2, the penicillin-binding protein of E. coli, and protecting Ceftazidime from enzymatic hydrolysis, AM-112 significantly enhances the antibacterial efficacy of Ceftazidime against Gram-negative bacteria, enterococci, and staphylococci. AM-112 exhibits favorable pharmacokinetic properties and acid-base stability. AM-112 can be used for the research of bacterial infections.

AGN 192403 (BRD4780) is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 is also a TMED9 inhibitor. AGN 192403 shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 can be used for glioma tumor and neurological diseases research.

3-Benzyl-3,9-diazaspiro[5.5]undecane is a PROTAC linker that can be used in the synthesis of PROTACs.

(R,R)-Birelentinib ((R,R)-DZD8586) (Compound 14) is a potent BTK inhibitor with IC50 values for BTK WT and BTK C481S of 0.7 and 0.86 nM, respectively. (R,R)-Birelentinib inhibits the self-phosphorylation of BTK and its IC50 is 24.3 nM. (R,R)-Birelentinib exhibits significant anti-proliferative activity against wild-type and C481S mutant HEK293 cells. (R,R)-Birelentinib can be used for the study of drug-resistant B-cell malignancies.

(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (4R,5S)-Nutlin carboxylic acid based MDM2 ligand and a linker used in PROTAC technology. (4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-29.

(+)-Adlumine (O-Methylcorledine) is an alkaloid derivative found in Corydalis ledebouriana.

GD3 Ganglioside ammonium is a prominent ganglioside of human melanoma. GD3 Ganglioside ammonium is an inducer of mitochondrial permeability. GD3 ganglioside ammonium directly targets mitochondria in a bcl-2-controlled fashion. GD3 ganglioside ammonium is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis.

dsP53-285 saRNA is a small activating RNA (saRNA) that readily activates wild-type p53 expression by targeting its promoter. dsP53-285 saRNA suppresses bladder cancer cells growth and metastasis.

C2NP sodium is a single-strand DNA aptamer that targets CD30. The multivalent C2NP is able to induce oligomerization of CD30 receptors and, in effect, activate downstream signaling, which led to apoptosis of anaplastic large cell lymphoma (ALCL) cells.

Beclanorsen is an antisense oligonucleotide targeted to the mRNA of the Bcl-2 oncoprotein.

Beclanorsen sodium is an antisense oligonucleotide targeted to the mRNA of the Bcl-2 oncoprotein.

aptTNF-α sodium is a TNF-α-targeting aptamer that has tissue protective effect and systemic anti-inflammatory effect upon acute tissue injury using the mouse acute lung injury (ALI) and acute liver failure (ALF) models.

Taurolithocholic acid is a taurine-conjugated tertiary bile acid. It induces apoptosis in hepatoma cell lines via caspase-3/7 activation and serves as a model to study the endocrine and metabolic roles of bile acids in enterohepatic circulation and liver physiology.

WEHI-7326 (WEHI 7326) is a specifi mitotic inhibitor and potential anticancer agent, causes cell cycle arrest in G2/M, cell death in vitro (MDA-MB-231 IC50=24.4 nM), and displays efficacious anti-tumor activity in vivo.WEHI-7326 induces cell death in a broad range of cancer cell lines, including taxane-resistant cells, and inhibits growth of human colon, brain, lung, prostate and breast tumors in mice xenografts.WEHI-7326 exceeded potency of myoseverin B by almost ten-fold, did not show any significant cytotoxic activity in vitro (IC50>40 uM) in HepG2 cells.WEHI-7326 prolongs survival in mouse models of high-risk neuroblastoma and leads to complete tumor regression when used in combination with standard-of-care relapse therapies.

DEBIO 1143 (Xevinapant, AT-406, SM406, ARRY-334543, D1143) is a potent, orally active Smac mimetic that antagonizes cIAP1, cIAP2 and XIAP with Ki of 66.4, 1.9 and 5.1 nM, respectively.

2'-O-Methylguanosine is a modified nucleoside produced in tRNAs by the action of tRNA guanosine-2’-O-methyltransferase. 2'-O-Methylguanosine results in apoptotic changes of cells.

RPL11-MDM2 inhibitor S9 (J012-3168) is a small-molecule RPL11 mimetic and potential inhibitor of RPL11-MDM2 interaction, directly binds MDM2 and induces p53 stabilization and activation.

A-1331852 is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL.

DC-5163 is a potent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with an IC50 of 176.3 nM and a Kd of 3.192 μM. DC-5163 can inhibit glycolysis pathway partially. DC-5163 also selectively inhibits cancer cell proliferation and induces apoptosis.

Ac-LEVD-CHO (TFA) is an inhibitor of caspase-4. Ac-LEVD-CHO (TFA) can inhibit the expression and secretion of IL-1α expression as well as the activation of caspase-4 induced by the T. denticola periodontal pathogen surface protein Td92 in human gingival fibroblasts. Ac-LEVD-CHO (TFA) can also reduce the apoptosis due to the expression of the dominant negative adenoviral RNA-dependent protein kinase in A549 and PC3 cancer cell lines.

NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improves the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.

Sphingosine (d18:1(14Z)) is an atypical sphingolipid that has a cis double bond at the 14-15 position. Sphingosine is a negative regulator of cell proliferation and can promote apoptosis.

LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research.

idoBR1 is an orally active amino acid with an amino sugar. idoBR1 can significantly inhibit LPS induced TNF-α production and MAPK signaling pathway. idoBR1 can inhibit bacteria and human sialidase. idoBR1 can inhibit bacterial and human sialidase and reduce the binding of CD44 to hyaluronic acid (HA). idoBR1 can reduce the release of pro-inflammatory factors and promote the generation of anti-inflammatory factors. idoBR1 can be used for research on inflammatory conditions.

CALR ligand 1 (Compound 2a) is a calreticulin (CALR) ligand. CALR ligand 1 shows antitumor activity against triple-negative breast cancer (TNBC) cells (IC50=0.1 μM). CALR ligand 1 induces intracellular calcium overloading and triggers apoptosis in TNBC cells. CALR ligand 1 is promising for research of TNBC .

MM927 is a potent NVL inhibitor, with an IC50 of 0.053 μM. MM927 blocks 60S ribosomal subunit biogenesis in the nucleolus. MM927 induces half-mer polysomes, cell cycle arrest at G1/S and G2/M and apoptosis in cells. MM927 demonstrates antitumor efficacy in MOLM-13 AML and HCT116 CRC xenograft models. MM927 can be used for the study of cancers such as acute myeloid leukemia (AML) and colorectal cancer (CRC).

RuOPt is a photoactivatable Ru(II)-Pt(IV) complex with reduced dark toxicity. Under irradiation, RuOPt induces apoptosis, generates ROS, and inhibits tumor spheroid growth, demonstrating comparable phototoxicity.